HEALTHCARE COSTS OF DLBCL IN ITALY: A REAL‑WORLD COMPARISON BETWEEN AXI‑CEL AND ELIGIBLE PATIENTS TREATED WITH NON‑CAR T ALTERNATIVES, AND THE IMPACT OF VEIN‑TO‑VEIN TIME (SIE 2026) - Oct 6, 2026 - Abstract #C038; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 4; "Post index, adjust- ed costs ratios were significantly higher among pts treated with alternative therapies (2.19x at ≥6 months, 2.06x at ≥9 and 2x at ≥12 months vs axi cel; p<0.01), mainly driven by repeated hospitalizations and treatment related resource use; CT and transplant related admissions accounted for most inpatient costs.Within the CAR T pathway, mean vari- able costs per pts were €9,757 during the VTV phase (ex- cluding acquisition costs of CAR T and DRG reimbursement) and €494 during ITD, largely attributable to supportive care (e.g., anakinra, tocilizumab) and transfusions.These real‑- world data show that axi‑cel is associated with lower down- stream HCRU compared with alternative non‑CAR T strate- gies. Importantly, strategies aimed at optimizing the VTV in- terval, such as faster manufacturing processes, optimized treatment capacity and slot availability, confer an economic benefit by reducing HCRU along the CAR T treatment..."
CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma
|
|
M. Martino1; A. Di Rocco2; Mc. Tisi3; V. Perrone4; S. Mazzoni4; L. Degli Esposti4; S. Sica5
|